Cancer Family
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
CI-CAN-00000175Explore in graph →
Non-malignant81 active trials1 approved drugs18 evidence items
- NCIt
- C27291
Loading cancer entity…
Cancer Family
CI-CAN-00000175Explore in graph →
Clinical trials
253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03778996 | SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma(HopES) | active not recruiting | Phase 2 | 31 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 |
| clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02657005 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 / Phase 2 | 85 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT06699472 | A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib | recruiting | Phase 2 | 22 | Fudan UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06564272 | A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma | recruiting | Phase 2 | 30 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04129151 | Palbociclib + Ganitumab In Ewing Sarcoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01336803 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI(Osteosarcoma) | completed | Phase 2 | 32 | Heike E Daldrup-LinkOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT04758000 | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse(Metform-Bone) | recruiting | Phase 2 | 67 | Istituto Ortopedico RizzoliOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT02511132 | A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma | completed | Phase 2 | 22 | Gradalis, Inc.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT03359005 | Irinotecan and Temozolomide for Ewing Sarcoma | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02727387 | Protocol for the Treatment of Metastatic Ewing Sarcoma(EW-2) | completed | Phase 2 | 155 | Italian Sarcoma GroupNETWORK | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT03275818 | Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma(ABRADES) | completed | Phase 2 | 69 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT00038142 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | terminated | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00001564 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02546544 | Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma(LINES) | completed | Phase 2 | 16 | University of OxfordOTHER | 5 | Jun 3, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03416517 | Anlotinib and Irinotecan for Ewing Sarcoma | unknown | Phase 1 / Phase 2 | 47 | Peking University People's HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00070109 | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | completed | Phase 2 | 50 | Children's Oncology GroupNETWORK | 2 | Sep 14, 2018 | clinicaltrials |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | terminated | Phase 2 | 219 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT01696669 | Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults | completed | Phase 2 | 43 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Aug 1, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Mar 19, 2025source: clinicaltrials